▲ +93.10% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Esperion Therapeutics in the last 3 months. The average price target is $52.89, with a high forecast of $134.00 and a low forecast of $24.00. The average price target represents a 93.10% upside from the last price of $27.39.
The current consensus among 9 polled investment analysts is to hold stock in Esperion Therapeutics. This rating changed within the last month from a Buy consensus rating.
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low-density lipoprotein cholesterol in the United States. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.